This study is looking at a new vaccine treatment for head and neck cancer that has come back or spread. The vaccine, called TMV, is made from a person's own tumor cells. This study will test the TMV vaccine alone and with another medicine called pembrolizumab, which helps the immune system fight cancer. The study will check if the treatments are safe, what side effects they might have, and the best dose to use.
- The study requires providing tissue from standard surgery, and includes up to 3 vaccine doses every 2 weeks.
- Participants might also receive pembrolizumab every 3 weeks for up to a year.
- There are regular check-ups and tests, including heart checks and blood samples.
To join, you must be at least 18, have certain types of head and neck cancer, and meet other health criteria. The study lasts about a year, with follow-ups. If you meet the requirements and are interested in new cancer treatments, this study might be an option.
How understandable was the trial content above?
Hard to understand
Easy to understand